Amgen psoriasis drug tops J&J's Stelara in Phase III study

November 11, 2014 9:54 PM

15 0

(Reuters) - Amgen Inc said on Tuesday that its experimental psoriasis drug, brodalumab, met all the goals of a late-stage study, clearing the rough skin patches associated with the disease more thoroughly than Johnson & Johnson's Stelara and a placebo.

Amgen is developing brodalumab under a multi-drug collaboration with AstraZeneca that involves splitting costs and eventual profits.

Read more

To category page